1. Hepatic antifibrotic effects of bezafibrate in vitro and in vivo models of liver fibrosis.
- Author
-
Reghelin CK, Bastos MS, de Souza Basso B, Costa BP, Cruz de Sousa A, Martha BA, Antunes GL, Nassr MT, Rosa Garcia MC, Matzenbarcher LS, Schneider Levorse VG, Costa Rodrigues Guma FT, Fagundes Donadio MV, Rodrigues de Oliveira J, and Alberto da Silva Melo D
- Abstract
Bezafibrate (BZF) is a drug that reduces cholesterol and triglyceride levels in the blood. Research indicates that BZF, through activation of PPAR receptors, regulates the expression of genes involved in lipid homeostasis, inflammation, cell differentiation, and proliferation. This study investigated the in vitro and in vivo effects of BZF on activated hepatic stellate cells (HSCs) and on carbon tetrachloride-induced liver fibrosis in mice. After 72 h of treatment in vitro, BZF decreased cell proliferation, reversed the phenotype, decreased cell contraction, and induced autophagy. In addition, BZF promoted a protective effect on tetrachloride-induced liver fibrosis in mice, through antifibrotic actions. These findings suggest that BZF may have a potential antifibrotic effect, which could emerge as a possible new therapy for the treatment of liver fibrosis., Competing Interests: Declaration of competing interest The authors affirm that there are no conflicts of interest. They have all reviewed and approved the manuscript for submission., (Copyright © 2025 Elsevier Ltd. All rights reserved.)
- Published
- 2025
- Full Text
- View/download PDF